Cadrenal Therapeutics Inc
CVKD
Company Profile
Business description
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
Contact
822 A1A North
Suite 306
Ponte VedraFL32082
USAT: +1 904 300-0701
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
4
Stocks News & Analysis
stocks
BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs
We plan to raise our fair value estimate of BlackRock stock.
stocks
Our view of ANZ’s strategic plan
Trying to please customers and shareholders with a simpler and leaner bank.
stocks
Perplexing buyback from overvalued ASX share
Earnings continue to grow but investor expectations are too high.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,279.10 | 2.00 | 0.02% |
| CAC 40 | 7,919.62 | 14.64 | -0.18% |
| DAX 40 | 24,236.94 | 150.99 | -0.62% |
| Dow JONES (US) | 46,270.46 | 202.88 | 0.44% |
| FTSE 100 | 9,452.77 | 9.90 | 0.10% |
| HKSE | 25,704.42 | 263.07 | 1.03% |
| NASDAQ | 22,521.70 | 172.91 | -0.76% |
| Nikkei 225 | 47,463.31 | 615.99 | 1.31% |
| NZX 50 Index | 13,311.80 | 34.81 | 0.26% |
| S&P 500 | 6,644.31 | 10.41 | -0.16% |
| S&P/ASX 200 | 8,973.00 | 4.30 | 0.05% |
| SSE Composite Index | 3,865.17 | 0.06 | -0.00% |